In this article
What are Dendritic Cells? "Nature’s Adjuvant"
Initially depicted in 1973 by Ralph Steinman and Zanvil Cohn, dendritic cells (DCs) have a fundamental job of interfering with intrinsic insusceptible reactions and fostering a flexible immune response. From that point forward, DCs were viewed as the most intense antigen-displaying cells (APCs), frequently referred to as “Nature’s adjuvant,” designed to initiate credulous and memory-resistant reactions. In terms of securing and managing antigens for introduction to T cells, DCs have a prevalent limit and express abnormal quantities of costimulatory or coinhibitory atoms that determine secure initiation or anergy1. Right about 40 years after that, when the Nobel Prize for Medicine or Physiology was awarded to Ralph Steinman in 2011 for his disclosure of these essential natural immune cells, the importance of DCs was perceived.
This immunotherapy treatment helps the body battle cancer cells with its own defense mechanism. Dendritic cell therapy is often used when regular therapies have not been effective. As of late, this treatment was proposed in India and multiple patients were relieved under the supervision of the renowned Oncologist with empowering results. Be that as it may, there are common drugs that have been developed over decades for most forms of tumor. Usage of these drugs is administered and combined with unsusceptible care, since it is realized that tumor cells weakened by chemotherapy or radiation are considerably easier to decimate with invulnerable cells than with flawless tumor cells.
Type of cancer treated with dendritic cell based immunotherapy treatment
- Skin cancer
- Kidney cancer
- Breast cancer
- Pancreatic cancer
- Colon cancer
- Ovarian cancer
- Prostrate cancer
Stage IV cancer treatment
Dendritic cell based immunotherapy treatment has proved to be quite a success specially with no hope stage IV cancer treatment. Patients specially on stage IV cancer can try and go for dendritic cell based immunotherapy in cancer treatment.
Hospitals for dendritic cell based immunotherapy treatment in India
- LDG India Ltd, Gurugram
- APAC Biotech, Noida
- Dendritic cell research, New Delhi
Cost of dendritic cell based immunotherapy treatment in India
Cost of dendritic cell based immunotherapy treatment may vary from $ 8000 USD – $ 15,000 USD depending upon stage of cancer and treating doctor and hospital
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.